Braveheart Bio Raises $382.5M in U.S. IPO to Battle Heart Disease
Heart disease-focused biotech Braveheart Bio has raised $382.5 million in its U.S. IPO. Investor Demand Beats Expectations The San Francisco-based ...
Agomab Therapeutics Nv (AGMB)
This company is not actively trading or the ticker does belong to another company in our database now.
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| 6.9800 (reported; USD unavailable) | 5,000 | USD value unavailable | 40,000 | 2026-11-05 | Filing | |
| 6.9100 (reported; USD unavailable) | 5,000 | USD value unavailable | 35,000 | 2026-11-05 | Filing | |
| 6.8100 (reported; USD unavailable) | 5,000 | USD value unavailable | 30,000 | 2026-11-05 | Filing | |
| 8.9000 (reported; USD unavailable) | 5,000 | USD value unavailable | 25,000 | 2026-10-21 | Filing | |
| 8.8600 (reported; USD unavailable) | 5,000 | USD value unavailable | 20,000 | 2026-10-21 | Filing |
News See All
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. AgomAB Therapeutics NV (NASDAQ:AGMB) is one of the best up and coming stocks on our list.
8 Best Up and Coming Pharmaceutical Stocks to Buy Now
In this article, we will be taking a look at the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now.
7 Best Strong Buy European Stocks to Invest In
In this article, we will look at the 7 Best Strong Buy European Stocks to Invest In. European stocks are getting a closer look as investors search beyond the crowded parts of the U.S.
Hedge Fund Resource Center